HPV疫苗與痛痛女孩

What are HeLa cells? A cancer biologist explains

In an amazing twist of fate, the aggressive cervical cancer tumor that killed Henrietta Lacks, a 31-year old African American mother, became an essential tool that helped the biomedical field flourish in the 20th century. As a cancer researcher who uses HeLa cells in my everyday work, even I sometimes find it hard to believe.

Lacks' cervical cancer cells, called "HeLa" after the first two letters of her first and last name, are immortal, continuing to divide when most cells would die. This ability to survive through endless generations of cells is what makes them invaluable for scientists conducting experiments on human cells.

(Author: Ivan Martinez; Illustrator: Cheng Han-wen; Editor: Chen Yun-ru)


Why HeLa cells matter

Before HeLa cells, scientists wanted a way to grow and study human cells in the lab to conduct studies that are impossible to do in a living person. When Lacks’ cervical cancer cells were successfully grown in a petri dish in 1951, scientists now had a source of cost-effective and easy-to-use cells that expanded their ability to conduct research. From polio and COVID-19 vaccines to cancer research and sequencing the human genome, HeLa cells have played an enormous role in many scientific discoveries and advancements.

Henrietta Lacks’ story is also an ongoing bioethics case, because these cells were taken from her during a routine cervical cancer biopsy that was then given to researchers without her consent, as was common practice at the time. The Lacks family has long attempted legal action against companies they say have unfairly benefited from Henrietta’s cells. A 2010 book by journalist Rebecca Skloot details how HeLa cells affected both science and the Lacks family.

The Lacks family wasn’t aware that Henrietta’s cells had been harvested until Rolling Stone magazine journalist Michael Rogers contacted them two decades after her death.

But how did Lacks’ cells become immortal?

Lacks didn’t know that cells in her cervix were infected with a virus that causes one of the most common sexually transmitted diseases: human papillomavirus, or HPV. There are more than 150 different types of HPVs, but only a small group are known to cause cervical cancer. In fact, 99.7% of cervical cancers are HPV positive. Fortunately, most people infected with high-risk HPVs are able to clear out the virus before it becomes cancerous. HPV vaccinations can prevent over 90% of HPV-related cancers. But 10% of people with HPV infections on their cervix develop cancer. Sadly, Henrietta was one of the unlucky ones.

Her misfortune has helped elucidate how HPV works. Since the Nobel Prize-winning 1976 discovery of HPVs essential role in cervical cancer, many scientists, including me, have been investigating how HPV causes cancer.

While some types of HPV cause warts on the skin, certain high-risk ones can cause cancer.

Two proteins

Turns out, the virus’ cancer-causing ability is linked to two proteins it produces. These viral proteins can target and destroy two major human proteins that protect against cancer, p53 and retinoblastoma (Rb). P53 and Rb act as sentinels making sure cells don’t accumulate harmful genetic mutations and stop dividing after a set number of cycles. My research has focused on how HPV proteins interact with tumor-suppressing proteins in different types of human cells, including HeLa.

Most cells divide around 40 to 60 times before they become too old to function properly and are naturally killed off. But HPV can allow cells to divide forever, because they attack the sentinels keeping uncontrolled division in check. After Lacks was infected with HPV 18, the second-most-common high-risk type of the virus, her cervical cells lost the ability to produce these sentinels. Without growth checks in place, her cells were able to divide indefinitely and became “immortal” – living on to this day both in test tubes and the 70,000 studies they’ve made possible.

(To read the Chinese version of this article, please click: 〈癌症生物學家看海拉細胞的不朽傳奇 〉)

*This article is republished from The Conversation under a Creative Commons license. Read the original article.

About The Conversation

The Conversation was founded in Melbourne, Australia in 2011. It is a unique collaboration between academics and journalists that in a decade has become the world’s leading publisher of research-based news and analysis.

The Conversation

誰幫我們完成這篇文章

艾文.馬汀涅茲 美國西維吉尼亞大學微生物學、免疫學和細胞生物學副教授,同時也是該校癌症研究所的研究員,正在研究RNA如何影響肺癌對放射治療的反應。 Associate Profes... 了解更多 鄭涵文 曾任記者寫很多字,現下更專心畫畫。平生無大志,喜用圖像化繁為簡、嘰嘰喳喳說故事。成就感來自觀者看圖後的會心一笑。 了解更多 陳韻如 新聞系畢業後,就投入編輯這份工作,非常努力讓每一篇報導都美美的呈現在讀者面前,希望你也喜歡這篇文章。 了解更多

你的參與,可以讓報導點亮世界

你的參與,
可以讓報導點亮世界

一篇豐富、精彩和專業的報導,要經過記者、攝影、設計師、編輯,還有許多專家才能完成,完成後還要靠著社群編輯、行銷企劃,才能送到你的眼前。我們所有的努力,都希望能幫助你更了解這個世界,更希望你對這個世界發出提問。讓每一篇報導點亮世界,訂閱我們、歡迎投稿。

歡迎訂閱
歡迎投稿

發布留言

隱私政策 許可協議

 

公益勸募許可字號|衛部救字第 1101363853 號

Copyright © 2023 The Reporter

公益勸募許可字號|衛部救字第 1101363853 號 隱私政策 許可協議